Everything you need to know to stay updated on the financial market. Information, trend and graph in real time on the stock exchange quotations of the major stocks on world stock exchanges.
ISIN code: GB0009895292
Sector: Healthcare technology
Industry: Biotechnology and Pharmaceuticals
AstraZeneca's shares are listed on the London LSE market under the ticker AZN.
View the share's historical listing on the LSE
Company Description
AstraZeneca Plc. It is a company of biopharmaceutical Anglo-Swedish. She is active in the scientific research, development and commercialization of prescription drugs for cardiovascular, metabolic, respiratory, inflammatory, autoimmune, oncological diseases, infections and central nervous system disorders. AstraZeneca works in over 100 countries with approximately 57.500 employees. There are 23 production sites located in 16 countries with approximately 10.200 employees. The group comprises 14 research centres, located in 8 countries, employing around 13.000 people. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR, and metformin XR, among others.
The main shareholders of AstraZeneca are:
| Shareholder | Actions | Date reported | % output | Value |
|---|---|---|---|---|
| Price (T. Rowe) Associates Inc | 82.322.522 | 29 set 2021 | 3,14% | 4.944.290.671 |
| Wellington Management Group, LLP | 47.105.051 | December 30 2021 | 1,79% | 2.743.869.220 |
| Primecap Management Company | 46.690.500 | December 30 2021 | 1,78% | 2.719.721.625 |
| Capital International Investors | 35.388.789 | December 30 2021 | 1,35% | 2.061.396.959 |
| Fisher Asset Management, LLC | 20.109.886 | December 30 2021 | 0,77% | 1.171.400.859 |
| GQG Partners LLC | 19.453.752 | December 30 2021 | 0,74% | 1.133.181.054 |
| Goldman Sachs Group Inc | 11.523.558 | 29 set 2021 | 0,44% | 692.104.893 |
| Bank of America Corporation | 10.609.822 | December 30 2021 | 0,40% | 618.022.131 |
| Franklin Resources Inc. | 10.097.008 | December 30 2021 | 0,38% | 588.150.716 |
| FMR, LLC | 8.514.001 | June 29, 2021 | 0,32% | 509.988.659 |
Economic and financial analysis of the company
AstraZeneca is an Anglo-Swedish multinational that was born in April 1999 with the merger of two pharmaceutical companies of excellence: Astra AB and Zeneca Group. It is based at the Cambridge Biomedical Campus of Cambridge, England. In addition to Cambridge, its research and development is concentrated in Gothenburg, Sweden and Gaithersburg, Maryland, USA.
It is engaged in the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease, cardiovascular and metabolic disease and oncology, as well as infection, neuroscience and gastrointestinal areas. In the last year AstraZeneca has risen to prominence as one of the producers of the vaccine for Covid-19.
The company is now part of world leaders of the pharmaceutical industry.
AstraZeneca is listed on the London Stock Exchange and is a constituent of the FTSE 100 index. It has secondary listings on Nasdaq OMX Stockholm, Nasdaq New York, Bombay Stock Exchange and the Indian National Stock Exchange.
Astrazeneca currently generates the majority of its turnover in America, a market which currently accounts for 39,9% of turnover. Continental Europe generates 24,3% of turnover with 8% in the UK. Then come the markets of Africa, Asia and Australia with a share of 27,8% of global turnover.
Among the partners we find adherium with which he works in 2015 to implement an inhalation treatment intended for patients with respiratory diseases that exploits the digital technologies of Adherium. Since 2017 Astrazeneca has allied with Unicancer, a company specializing in the fight against cancer, to create a partnership aimed at carrying out clinical research to implement a national plan to fight against cancer in Algeria. Also in 2017 he formed a partnership with Merck in the oncology sector with the aim of conducting research on the development of certain types of cancer with targeted clinical trials.
Le multinational company I'm:
- AstraZeneca UK Limited – Great Britain – 100%
- AstraZeneca Reinsurance Limited – Great Britain – 100%
- AstraZeneca Treasury Limited – Great Britain – 100%
- NV AstraZeneca SA – Belgium – 100%
- AstraZeneca Dunkerque Production SCS – France – 100%
- AstraZeneca SAS – France – 100%
- AstraZeneca GmbH – Germany – 100%
- AstraZeneca Holding GmbH – Germany – 100%
- AstraZeneca SpA and Simesa SpA – Italy – 100%
- AstraZeneca Farmaceutica Spain SA – Spain – 100%
- AstraZeneca AB – Sweden – 100%
- AstraZeneca BV – Netherlands – 100%
- AstraZeneca Canada Inc. – Canada – 100%
- IPR Pharmaceuticals Inc. – Puerto Rico – 100%
- AstraZeneca LP – USA – 99%
- AstraZeneca Pharmaceuticals LP – USA – 100%
- Zeneca Holdings Inc. – USA – 100%
- AstraZeneca Pty Limited – Australia – 100%
- AstraZeneca KK – Japan – 80%
- Astra Tech – Sweden – 100%
The latest news on Astrazeneca
Pharmaceuticals, the big names are moving: Astrazeneca buys, Pfizer sells. From Recordati increased coupon with an eye on opportunities
Big maneuvers among the big American companies with M&A operations. Meanwhile, the Italian Recordati is thinking about targeted M&A operations in its new plan to 2025
AstraZeneca strengthens its position in oncology therapies and buys the Chinese Gracell for 1,2 billion
Astrazeneca's aim is to strengthen itself in the field of innovative cell therapies for the treatment of cancer and autoimmune diseases
Astrazeneca buys Icosavax vaccines for 1,1 billion. Offered $15 per share
Under the agreement, if some goals are achieved, the premium will also be 91% compared to Monday's close. Vaccines against respiratory viruses will be developed
Astrazeneca will buy the American CinCor Pharma. The deal is worth up to $1,8 billion
The cash portion represents approximately $1,3 billion in transaction value and a 121% premium. The maximum value of the acquisition with the potential exercise of the right would be $1,8 billion and would have a premium of 206%. For Astrazeneca it represents a strengthening in the cardiorenal sector
Astrazeneca acquires TeneoTwo for 1,26 billion and strengthens its anti-cancer treatments
The deal also includes the investigational clinical-stage T-cell treatment, TNB-486, which strengthens the hematologic cancer pipeline.